Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Cash & Equivalents (2020 - 2025)

Mereo BioPharma (MREO) has disclosed Cash & Equivalents for 6 consecutive years, with $41.0 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 41.27% to $41.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $41.0 million through Dec 2025, down 41.27% year-over-year, with the annual reading at $41.0 million for FY2025, 41.27% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $41.0 million at Mereo BioPharma, down from $48.7 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $127.1 million in Q4 2021, with the low at $41.0 million in Q4 2025.
  • Average Cash & Equivalents over 5 years is $67.9 million, with a median of $62.5 million recorded in 2025.
  • The sharpest move saw Cash & Equivalents surged 310.18% in 2021, then tumbled 46.36% in 2022.
  • Over 5 years, Cash & Equivalents stood at $127.1 million in 2021, then crashed by 46.36% to $68.2 million in 2022, then dropped by 15.78% to $57.4 million in 2023, then increased by 21.56% to $69.8 million in 2024, then tumbled by 41.27% to $41.0 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $41.0 million, $48.7 million, and $56.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.